Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–FDA accepts filing for fenebrutinib, an investigational BTK inhibitor, for relapsing (RMS) and primary progressive (PPMS) multiple sclerosis.